Welcome to our dedicated page for Incyte SEC filings (Ticker: INCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Incyte Genomics Inc (INCY) SEC filings page on Stock Titan aggregates regulatory documents for Incyte Corporation, a global biopharmaceutical company focused on Oncology and Inflammation & Autoimmunity. These filings provide structured insight into how the company reports its financial condition, governance changes and material events to the U.S. Securities and Exchange Commission.
Incyte’s common stock is listed on The Nasdaq Stock Market LLC under the symbol INCY, as disclosed in Form 8‑K reports. Investors can review current reports on Form 8‑K that cover topics such as quarterly financial results, executive and board transitions, inducement equity awards and key corporate agreements. For example, recent 8‑Ks describe leadership changes in the chief executive officer and chief financial officer roles, transition and employment agreements, and announcements of quarterly earnings press releases.
Alongside 8‑Ks, users can access Incyte’s annual reports on Form 10‑K and quarterly reports on Form 10‑Q (when available in the feed) to understand segment focus, risk factors, research and development priorities, and other disclosures that frame the company’s oncology and immunology strategy. These periodic reports typically detail the status of marketed products and pipeline programs, capital structure and significant accounting policies.
For those tracking management incentives and ownership, the filings page also links to insider transaction reports on Form 4 and related beneficial ownership disclosures, where present in EDGAR. These documents show grants of stock options, restricted stock units and performance shares, such as inducement awards and executive compensation packages referenced in Incyte’s current reports.
Stock Titan enhances this information by providing AI-powered summaries that explain the key points of lengthy filings, highlight notable changes and help readers interpret complex legal and financial language. Real‑time updates from EDGAR ensure that new INCY filings—whether earnings‑related, governance‑related or tied to material clinical and commercial developments—are quickly reflected, allowing investors, researchers and other stakeholders to review the underlying documents and AI insights in one place.
Incyte Corporation announced several executive leadership changes. Pablo J. Cagnoni was appointed President, Incyte and Global Head of Research and Development, adding broader enterprise-wide strategic and operational responsibilities while continuing to lead R&D. Steven H. Stein became Executive Vice President, Chief Medical Officer and Head of Late-stage Development, continuing to oversee late-stage programs in Hematology, Oncology and Immunology and Global Medical Affairs.
Mohamed Issa was appointed Executive Vice President and Head of U.S. Commercial, continuing to lead U.S. Oncology and taking on expanded responsibility for U.S. Immunology as these businesses are integrated into a single U.S. commercial organization. William J. Meury remains Chief Executive Officer and a member of the Board, while Matteo Trotta, Executive Vice President and General Manager, U.S. Dermatology, will leave Incyte following a transition period. The filing states there were no changes to compensation arrangements for the impacted executives in connection with these title changes.
INCYTE CORP President, R&D Pablo J. Cagnoni exercised stock options and then sold shares in a routine liquidity transaction. He exercised options to acquire 7,166 shares of common stock at $61.18 per share and 11,501 shares at $64.25 per share, totaling 18,667 shares. On the same day, he sold 18,667 common shares at an average price of $94.24 per share. After these transactions, his reported direct ownership was 234,800 common shares, which the notes state includes 229,661 shares underlying previously reported unvested restricted and performance stock units.
INCY reports a Form 144 notice for the sale of 18,667 shares of Common Stock via a stock option exercise on 03/17/2026. The filing lists proceeds of 1,759,101.55 and shows prior sales in the past three months associated with Pablo Cagnoni. The transaction is reported through Morgan Stanley Smith Barney LLC as broker-dealer.
Incyte Corporation reported that on February 27, 2026, the U.S. Food and Drug Administration issued a Complete Response Letter for the supplemental Biologics License Application for Zynyz (retifanlimab-dlwr) injection in metastatic non-small cell lung cancer in combination with platinum-based chemotherapy.
The FDA’s letter cited regulatory compliance inspection findings at Catalent Indiana, the third-party fill-finish facility referenced in the application, as the sole approvability issue. The FDA did not raise concerns about Zynyz’s efficacy, safety data in NSCLC, or the third-party drug substance manufacturer. Incyte is working with the FDA and Catalent Indiana to address the letter and support a potential resubmission.
INCYTE CORP President, R&D Pablo J. Cagnoni reported multiple equity transactions. On February 19, 2026, he exercised employee stock options into 13,093 and 5,575 shares of common stock at exercise prices of $61.76 and $61.18 per share, respectively, through derivative conversions.
He then executed an open-market sale of 18,668 shares of common stock at an average price of $100.91 per share. After these transactions, he directly owned 234,800 shares of common stock, plus remaining stock options, and had an additional 229,661 shares tied to unvested restricted and performance stock units.
Baker Bros. Advisors and affiliates filed Amendment No. 32 to their Schedule 13D on Incyte Corp., updating their large ownership position and related rights. The filing reports beneficial ownership of up to 31,213,417 shares of Incyte common stock by certain reporting persons, representing 15.7% of the outstanding shares as of February 3, 2026, including 108,931 vested stock options held by Julian C. Baker as director compensation.
The amendment also discloses a February 6, 2026 Registration Rights Agreement giving the Baker-managed funds resale registration rights for all of their Incyte securities. Incyte must, upon request, file and maintain a resale shelf registration and permit limited underwritten offerings and block trades for up to ten years, enhancing flexibility for future sales by the funds.
Incyte Corporation is a global biopharmaceutical company focused on hematology, oncology, and inflammation and autoimmunity. It discovers, develops and commercializes proprietary therapies from hubs in Wilmington, Delaware, Europe, Japan and Canada.
In hematology, key products include JAKAFI/JAKAVI (ruxolitinib) for myelofibrosis, polycythemia vera and graft-versus-host disease, ICLUSIG for certain leukemias, MONJUVI/MINJUVI for diffuse large B‑cell lymphoma and follicular lymphoma, and NIKTIMVO for chronic graft-versus-host disease. The company highlights strong reliance on JAKAFI/JAKAVI revenue as a principal risk.
In oncology, Incyte markets PEMAZYRE for cholangiocarcinoma and myeloid/lymphoid neoplasms with FGFR rearrangements, and ZYNYZ for Merkel cell carcinoma and squamous cell carcinoma of the anal canal. In inflammation and autoimmunity, OPZELURA (ruxolitinib cream) is approved for atopic dermatitis and nonsegmental vitiligo, with additional late-stage programs in hidradenitis suppurativa, vitiligo, prurigo nodularis and asthma via oral JAK1 inhibitor povorcitinib.
Incyte expands its portfolio with late-stage assets such as mutant CALR antibody INCA033989 for essential thrombocythemia and myelofibrosis, KRAS G12D inhibitor INCB161734, CDK2 inhibitor INCB123667, and TGFβR2xPD‑1 bispecific INCA33890. Strategic collaborations with Novartis, Lilly, Syndax, MacroGenics and others provide milestones and royalties, while a broad patent estate and regulatory exclusivities protect major products into the 2030s.
Incyte reported strong growth for Q4 and full-year 2025 and set higher 2026 revenue targets. Total revenue reached $1.51 billion in the fourth quarter, up 28% year over year, and $5.14 billion for 2025, up 21%, driven mainly by a 20% increase in net product revenue to $4.35 billion.
Key brands Jakafi and Opzelura grew solidly, while newer oncology products Niktimvo and Zynyz contributed increasing sales. GAAP net income jumped to $1.29 billion for 2025, with diluted EPS of $6.41, reflecting both higher revenue and the absence of large one-time R&D charges recorded in 2024.
For 2026, Incyte guides total net product revenue to $4.77–$4.94 billion, including Jakafi of $3.22–$3.27 billion, Opzelura of $750–$790 million, and hematology/oncology products of $800–$880 million. The company also plans substantial R&D and SG&A investment while advancing multiple late-stage trials and preparing for potential new launches.
Vijay Iyengar filed a notice to sell 12743 shares of Incyte (INCY) common stock under Rule 144. The shares are to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ, with an aggregate market value of 1388987.00.
The filing states that 196322703 shares of common stock were outstanding. The 12743 shares to be sold were acquired on 02/09/2026 via a stock option exercise paid in cash the same day. The notice also reports prior sales over the past three months, including 95811 shares sold on 01/06/2026 for gross proceeds of 9998255.70.